Ocean Biomedical Appoints New CMO, Elects Director
Ticker: OCEA · Form: 8-K · Filed: Oct 29, 2024 · CIK: 1869974
Sentiment: neutral
Topics: management-change, board-election, personnel
Related Tickers: OCEA
TL;DR
Ocean Biomedical brings in a new CMO and adds a director to the board.
AI Summary
Ocean Biomedical, Inc. announced on October 23, 2024, the appointment of Dr. Jonathan Roth as Chief Medical Officer and the election of Dr. David Lee to its Board of Directors. The company also reported on compensatory arrangements for its officers. This filing is a current report under the Securities Exchange Act of 1934.
Why It Matters
The appointment of a new Chief Medical Officer and a board member can signal strategic shifts or new directions for the company's medical and governance strategies.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can indicate internal shifts that may impact the company's future performance and strategy.
Key Players & Entities
- Ocean Biomedical, Inc. (company) — Registrant
- Dr. Jonathan Roth (person) — Appointed Chief Medical Officer
- Dr. David Lee (person) — Elected to Board of Directors
- October 23, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Jonathan Roth has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Dr. David Lee has been elected to the Board of Directors.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is October 23, 2024.
What type of SEC filing is this?
This is a Form 8-K, a Current Report.
What is the state of incorporation for Ocean Biomedical, Inc.?
Ocean Biomedical, Inc. is incorporated in Delaware.
Filing Stats: 450 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-10-29 16:45:14
Key Financial Figures
- $0.0001 — ction 12(b) of the Act: Common Stock, $0.0001 par value OCEA The Nasdaq Stock Mar
- $11.50 — of common stock at an exercise price of $11.50 OCEAW The Nasdaq Stock Market LLC
Filing Documents
- form8-k.htm (8-K) — 41KB
- 0001493152-24-042911.txt ( ) — 259KB
- ocea-20241023.xsd (EX-101.SCH) — 3KB
- ocea-20241023_def.xml (EX-101.DEF) — 29KB
- ocea-20241023_lab.xml (EX-101.LAB) — 36KB
- ocea-20241023_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 5KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 23, 2024 OCEAN BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-40793 87-1309280 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 55 Claverick St. , Room 325 Providence , RI 02903 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (401) 444-7375 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Common Stock, $0.0001 par value OCEA The Nasdaq Stock Market LLC Warrants, each warrant exercisable for one share of common stock at an exercise price of $11.50 OCEAW The Nasdaq Stock Market LLC (Title of Each Class) (Trading Symbol) (Name of Each Exchange on Which Registered) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (CFR 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (CFR 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Appointment of an Officer. On October 23, 2024, Elizabeth Ng notified the Company's Board of Directors that she would be taking a sabbatical for personal reasons. Director, M. Michelle Berrey was appointed to act as Interim Chief Executive Officer, effective immediately. There have been no compensation arrangements made, and when determined by the Company's Compensation Committee, such arrangements shall be disclosed pursuant to a Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 29, 2024 OCEAN BIOMEDICAL, INC. By: /s/ Jolie Kahn Jolie Kahn Chief Financial Officer